List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
Boehringer Ingelheim and Eli Lilly and Company has received a…
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
Comprehensive Phase III UniTinA-asthma™ program ongoing...
22 May 2012 | By Boehringer Ingelheim
Comprehensive Phase III UniTinA-asthma™ program ongoing...
Olodaterol significantly improved lung function (FEV 1) for at least…
21 May 2012 | By Boehringer Ingelheim
Olodaterol significantly improved lung function (FEV 1) for at least 24 hours compared to placebo...
New data on TWYNSTA®...
29 April 2012 | By Boehringer Ingelheim
New data on TWYNSTA®...
The final patient has been randomised to treatment in the…
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a…
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
Phase II clinical trial results...
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
The CHMP issued a Positive Opinion recommending the approval of…
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
Boehringer Ingelheim and Eli Lilly received a positive opinion from…
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
TWYNSTA® leads to prompt and very effective reductions in blood…
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today…
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
